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  29 
Abstract 30 
Myostatin inhibition is thought to improve whole body insulin sensitivity and mitigate 31 
the development of insulin resistance in models of obesity. However, although 32 
myostatin is known to be a major regulator of skeletal muscle mass, the direct effects 33 
of myostatin inhibition in muscle on glucose uptake and the mechanisms which may 34 
underlie this are still unclear. We investigated the effect of local myostatin inhibition 35 
by adeno-associated virus-mediated overexpression of the myostatin pro-peptide on 36 
insulin-stimulated skeletal muscle glucose disposal in chow-fed or high fat diet-fed 37 
mice and evaluated the molecular pathways that might mediate this. We found that 38 
myostatin inhibition improved glucose disposal in obese high fat diet-fed mice 39 
alongside the induction of muscle hypertrophy, but did not have an impact in chow-40 
fed mice. This improvement was not associated with greater glucose transporter or 41 
peroxisome proliferator-activated receptor gamma coactivator-1α expression or 5’ 42 
AMP-activated protein kinase activation as previously suggested. Instead, 43 
transcriptomic analysis suggested that the improvement in glucose disposal was 44 
associated with significant enrichment in genes involved in fatty acid metabolism and 45 
translation of mitochondrial genes. Thus, myostatin inhibition improves muscle 46 
insulin-stimulated glucose disposal in obese high fat diet-fed mice independent of 47 
muscle hypertrophy, potentially involving previously unidentified pathways. 48 
 49 
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  52 
Introduction 53 
The development of skeletal muscle insulin resistance is an important feature of type 54 
2 diabetes because skeletal muscle is a major site of post-prandial glucose uptake. 55 
In addition, the development of insulin resistance is thought to be a feature of the 56 
loss of muscle mass during aging, known as sarcopenia. Inhibition of myostatin, a 57 
negative regulator of muscle size, has received significant attention as a potential 58 
therapeutic strategy for the improvement of both muscle strength (32) and insulin 59 
sensitivity (5), and the mitigation of the pathological features of the metabolic 60 
syndrome. Myostatin is a member of the transforming growth factor-β family of 61 
proteins that is secreted and activates Smad2/3 signalling in cells in an 62 
autocrine/paracrine fashion by binding the activin type 2A and 2B receptors (20). It is 63 
expressed predominantly in muscle and (at the mRNA level) at much lower levels in 64 
adipose tissue (1). 65 
 66 
Knockout of the myostatin gene causes significant enlargement of skeletal muscles 67 
through both hyperplasia and hypertrophy (24), but this increase in muscle mass is 68 
not mirrored by an increase in muscle strength (2). In contrast, post-natal inhibition of 69 
myostatin causes muscle hypertrophy, but not hyperplasia, (3, 19), and results in a 70 
concomitant increase in muscle strength (12, 23). Much less is known about the 71 
effect of myostatin inhibition on muscle glucose uptake and insulin sensitivity. 72 
Myostatin gene knockout prevents fat mass gain during the lifespan of chow-fed 73 
mice (25) and most evidence indicates that the genetic loss of myostatin improves 74 
glucose tolerance and/or insulin sensitivity in mouse models of (extreme) obesity 75 
(13, 14, 40). Post-natal systemic myostatin antibody treatment increases skeletal 76 
muscle mass  (4, 5, 18, 34, 39) and increases whole body insulin sensitivity in aged 77 
chow-fed mice, but not young mice being fed either regular chow or a high fat diet 78 
(5). Thus, myostatin inhibition-induced muscle hypertrophy is not always 79 
accompanied by an increase in insulin sensitivity, suggesting that hypertrophy is not 80 
sufficient and another, muscle mass-independent effect is required or that a potential 81 
threshold in the increase in muscle mass exists for an effect on insulin sensitivity to 82 
occur.  83 
In addition, the mechanism through which myostatin acts to improve insulin 84 
sensitivity in skeletal muscle remains unclear. Systemic administration or 85 
overexpression of myostatin inhibitors affects the action of myostatin originating 86 
from, and acting on, other tissues important for controlling whole body insulin 87 
sensitivity, such as white and brown adipose tissue (33). Thus, it remains unclear 88 
whether myostatin inhibition improves muscle insulin sensitivity in models of insulin 89 
resistance through a local effect or whether this effect is mediated by alterations in 90 
systemic factors. Myostatin inhibition has been proposed to stimulate signalling 91 
through the Akt pathway (36) and to increase 5’ AMP-activated protein kinase 92 
(AMPK) activity (11, 43) in skeletal muscle. These pathways control the translocation 93 
of glucose transporters to the plasma membrane as part of insulin-dependent and 94 
insulin-independent signalling mechanisms, respectively (16, 17). In addition, we 95 
have previously shown greater expression of the GLUT1 and GLUT4 glucose 96 
transporters after local myostatin inhibition, which was associated with enhanced 97 
muscle glucose disposal in rat muscle (8). Finally, myostatin inhibition-dependent 98 
activation of an AMPK-peroxisome proliferator-activated receptor gamma coactivator 99 
(PGC)-1α pathway has been suggested to stimulate the formation of brown fat by 100 
increasing the secretion of the hormone irisin from skeletal muscle (30).  101 
 102 
Generation of active myostatin requires cleavage and subsequent dimerization of a 103 
precursor protein. The NH2-terminal latency-associated peptide (ProMyo) sequesters 104 
the myostatin dimer and prevents it from binding to the activin type 2A and 2B 105 
receptors (20). Here, we show that local skeletal muscle myostatin inhibition using 106 
an adeno-associated virus (AAV) expressing the ProMyo peptide increases insulin-107 
stimulated glucose uptake in high-fat diet-fed mice, but not in chow-fed mice despite 108 
the presence of significant muscle hypertrophy. In contrast to previous work, this was 109 
not associated with increased PGC-1α or glucose transporter expression.  110 
 111 
  112 
Methods 113 
Preparation of adeno-associated virus 114 
The adeno-associated virus (AAV) construct containing a modified myostatin 115 
propeptide sequence fused to a mouse immunoglobulin G2a (IgG2a) moiety under 116 
control of a CAGG promoter was as previously described (12, 41).  AAV2/8 ProMyo 117 
viral particles were produced and titered by Vector Core (Nantes, France). 118 
Animals 119 
Male C57BL/6 mice (Harlan Laboratories) and myostatin knockout mice on a 120 
C57BL/6 background (24) were housed in animal facilities at the Royal Veterinary 121 
College or the University of Reading under a 12:12 hour day-night cycle with 122 
standard chow or a high fat diet and water available ad libitum. The high fat diet was 123 
obtained from Research Diets (New Brunswick, USA; #D12451), and contained 45% 124 
of calories derived from fat (lard and soy bean oil), 35% from carbohydrates and 125 
20% from protein. All experimental procedures were carried out under a United 126 
Kingdom Home Office licence in compliance with the Animals (Scientific Procedures) 127 
Act 1986. 128 
 129 
For intramuscular administration of AAV8 ProMyo, mice were anaesthetized with 130 
isoflurane (4% induction, 2% maintenance) and the anterior aspect of the lower limbs 131 
was shaved. AAV ProMyo (5x1010 virus particles in 50 µl PBS-MK) was injected into 132 
the cranial compartment of the left lower leg with a 29-gauge insulin syringe, while 133 
the right leg was injected with 50 µl PBS-MK as a paired control. 134 
 135 
Intraperitoneal insulin and glucose tolerance tests 136 
For intraperitoneal insulin tolerance tests (IPITT), mice were fasted for 3–4 hours 137 
before administering insulin. Insulin was prepared at 100 iu/ml in normal saline and 138 
used to resuspend nitrogen-dried 2-[1,2-3H(N)]-deoxy-D-glucose (0.37 MBq). Basal 139 
blood glucose was measured in tail blood with an Accu-Check Advantage meter 140 
(Roche Diagnostics, Burgess Hill, West Sussex, UK). A further 10 µl of blood was 141 
collected in microfuge tube containing 1 iu heparin in saline, mixed and placed on 142 
ice. Immediately afterwards, insulin and deoxyglucose tracer was administered 143 
intraperitoneally at a dose of 0.75 iu/kg. At 15, 30, 60 and 90 minutes after insulin 144 
administration, blood glucose was measured as described above. After taking the 145 
final blood sample, the mice were euthanized by cervical dislocation and tibialis 146 
cranialis (TC), extensor digitorum longus, soleus muscles and epididymal fat pads 147 
were collected, weighed and frozen in liquid nitrogen-cooled isopentane. 148 
Intraperitoneal glucose tolerance test (IPGTT) was conducted and glucose clearance 149 
into TC muscle was determined as described previously (7). 150 
 151 
In vivo study design 152 
For the time course analysis of the effect of myostatin inhibition, 3-month-old 153 
C57BL/6 males were given an intramuscular injection of AAV ProMyo as described 154 
above, and were kept for 1, 2, 4 or 10 weeks before being subjected to an IPITT or 155 
an IPGTT, after which they were euthanized and their muscles harvested and snap-156 
frozen (n=10 per time point). 157 
 158 
To determine the effect of myostatin inhibition in HFD-fed mice, C57BL/6 males were 159 
switched from regular chow to high fat diet (HFD) at 8 weeks of age, while 160 
contemporaneous controls were kept on a normal chow diet. Four weeks later, mice 161 
were given intramuscular injections of AAV8 ProMyo into one TC muscle, while the 162 
contra-lateral limb was injected with saline. Mice were kept for 2 or 10 weeks post-163 
injection, after which mice (n=10 per group) underwent an IPITT, before euthanasia 164 
and muscle collection. The remaining mice were euthanized and their muscles were 165 
harvested without undergoing an IPITT (n=8 per group). 166 
 167 
RNA analysis 168 
TC muscles from mice harvested without IPITT 10 weeks after AAV or saline 169 
injection were homogenized in Tri-reagent (Sigma-Aldrich) and RNA was extracted 170 
according to the manufacturer’s instructions. One microgram of RNA was reverse 171 
transcribed using a qScript cDNA synthesis kit (Quanta Biosciences). Transcript 172 
levels were quantified in duplicate by real-time PCR using PerfeCta SYBR Green 173 
FastMix (Quanta Biosciences). A serial dilution of a mixture of cDNA from all 174 
samples was prepared and used to construct a standard curve for relative 175 
quantification of target transcripts, expression of which were normalized to that of 176 
CNSK2A2, a reference gene which was defined after geNorm analysis 177 
(https://genorm.cmgg.be/). The primer sequences used are listed in Table 1. 178 
For microarray analysis, independent pooled RNA samples were prepared by mixing 179 
500 ng total RNA from four independent samples to create two RNA pools from both 180 
ProMyo-overexpressing and saline-injected muscle samples. Total RNA integrity for 181 
each replicate was determined using by Bioanalyzer on a RNA Pico Chip (Agilent 182 
Technologies, as per manufacturer’s instructions). For microarray analysis, labelled 183 
extracts were prepared from total RNA samples using the Nugen Ovation V2 system 184 
followed by Nugen Encore Biotin Labelling Kit (Nugen Technologies Inc, as per 185 
manufacturer’s instructions). Subsequently, samples were hybridized to Affymetrix 186 
Mouse 430_2 GeneChips as per manufacturer’s guidelines (Nugen Technologies Inc 187 
and ThermoFisher Scientific)   188 
 189 
Raw intensity data were processed with the RMA algorithm with quantile 190 
normalisation using the Affymetrix Expression Console software. The resulting 191 
expression data were subjected to gene set enrichment analysis (GSEA) (26, 35) 192 
using GSEA software v_3.0. Input data were the bi-weight average signal (log2). 193 
Genes without a gene symbol were excluded and data were collapsed into single 194 
gene symbols before the analysis, using the median expression value for each gene 195 
symbol (20630 genes remained). All genes were ranked on the basis of differential 196 
expression between ProMyo and saline-injected muscles, defined as the real values 197 
of Diff_of_Classes. Three separate GSEA runs were performed; one with the gene 198 
sets KEGG_FATTY_ACID_METABOLISM, 199 
KEGG_OXIDATIVE_PHOSPHORYLATION and 200 
KEGG_INSULIN_SIGNALING_PATHWAY, one with ten gene sets related to 201 
inflammation (see table 2) and one with collection c5.all.v6.1, a collection of 5,917 202 
gene sets based on gene ontologies. All gene sets were obtained from Molecular 203 
Signature Database v6.1. GSEAs were run with permutation of gene sets (n=1,000), 204 
using the weighted enrichment statistic, and default parameters for gene set size 205 
(minimum size 15, maximum size 500). A false discovery rate of <0.05 was accepted 206 
as being significant. Subsequent Leading Edge Analysis was performed to determine 207 
overlap between significantly enriched gene sets in genes mostly responsible for the 208 
enrichment score. 209 
The microarray data have been uploaded to Gene Expression Omnibus (accession 210 
GSE130622). Output enrichment plots for gene sets listed in table 2 are available 211 
upon request.  212 
 213 
 214 
Western blotting 215 
Liquid nitrogen-powdered muscle was lysed in cold RIPA buffer (50 mM TRIS-HCl 216 
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% v/v Nonidet P40 substitute, 0.25% sodium 217 
deoxycholate, plus freshly added protease inhibitor cocktail (Sigma), phosphatase 218 
inhibitor cocktail (Sigma) and 20 mM beta-glycerophosphate). Protein concentration 219 
was determined using the Bio-rad DC protein assay. Samples were adjusted to the 220 
same concentration with RIPA buffer and SDS-PAGE loading buffer containing beta-221 
mercaptoethanol (2% final concentration) was added. Samples containing 40 µg 222 
protein were separated on pre-cast 4–12% Bis-Tris gels (Life Technologies) and 223 
blotted onto PVDF membranes. Membranes were blocked in 5% non-fat dried milk in 224 
Tris-buffered saline with 0.5% tween-20 (TBS-T) and incubated overnight at 4°C with 225 
primary antibody diluted in TBS-T, 5% BSA. Membranes were subsequently 226 
incubated with horseradish-conjugated species-specific secondary antibodies 227 
(Millipore) in TBS-T containing 5% non-fat milk powder. Membranes were washed 3 228 
× 5 min in TBS-T after each step. Antibodies were then detected with ECL Plus (Bio-229 
rad) and an ImageQuant LAS4000 mini (GE Healthcare). The following primary 230 
antibodies were used:  anti-Akt #9272, anti-pSer473-Akt #9271, anti-AMPKα #2532, 231 
anti-pThr172-AMPKα, anti-ACC #3662, anti-pSer79-ACC #3661, anti-α-actinin 232 
#6487, anti-GAPDH #5174 and anti-Cblb #9498 from Cell Signaling Technology; 233 
anti-PGC-1α #54481 and OXPHOS antibody cocktail #110413 from Abcam; and 234 
anti-GLUT4 #sc-53566 from Santa Cruz Biotechnology. 235 
 236 
Statistical analysis 237 
Statistical analyses were carried out using SigmaPlot v12.3 or GraphPad Prism v6. 238 
Data from time course experiments, and experiments involving different diets and 239 
myostatin inhibition were analysed with Two-Way Repeated Measures ANOVA, with 240 
time or myostatin inhibition as the paired factor. The Sidak-Holm method was used 241 
for post-hoc testing. Two-group comparisons were performed using t-tests, after 242 
verifying equality of variance and normality. The threshold for statistical significance 243 
was set at p<0.05. Data are displayed as mean ± standard error of the mean 244 
(S.E.M), or as mean plus individual data points. 245 
  246 
Results 247 
 248 
Myostatin inhibition increases muscle size, but not insulin-stimulated glucose 249 
disposal in chow-fed mice 250 
Overexpression of ProMyo in TC muscles of chow-fed mice for 1, 2, 4 or 10 weeks 251 
resulted in significant muscle hypertrophy in wild-type mice (Figure 1A) but not in 252 
myostatin knockout mice (Figure 1B). As expected, muscle mass was substantially 253 
higher in the myostatin knockout mice compared to the wild type mice (Figure 1A 254 
&1B). However, inhibition of the activin type 2B receptor has been shown to lead to 255 
additional hypertrophy in myostatin knockout mice (21) and the absence of such an 256 
effect of AAV ProMyo on muscle mass in the knockout mice implies that the 257 
construct is myostatin-specific. Insulin-stimulated glucose disposal, as measured by 258 
IPITT, was not different between saline- and AAV ProMyo-injected muscles at any of 259 
the time points (Figure 1C). Total glucose uptake into muscle was higher after 4 and 260 
10 weeks ProMyo overexpression by virtue of the significant increases in muscle 261 
mass (Figure 1D). As we have previously demonstrated higher muscle glucose 262 
uptake per unit muscle mass in ProMyo overexpressing rat muscle during a glucose 263 
tolerance test (IPGTT) (8), we measured glucose uptake during an IPGTT in mice 264 
after two weeks of ProMyo overexpression. However, we found no difference in 265 
glucose uptake between saline and AAV-ProMyo-injected muscles (Figure 1E). 266 
These data suggest that although myostatin inhibition-induced muscle hypertrophy 267 
increases total glucose disposal into muscle under conditions of hyperinsulinaemia, 268 
muscle glucose uptake per unit muscle mass is not increased by myostatin inhibition 269 
in chow-fed mice. 270 
 271 
Myostatin inhibition increases insulin-stimulated glucose disposal in muscle of HFD-272 
fed mice 273 
We next investigated whether local myostatin inhibition would improve muscle 274 
glucose uptake in HFD-fed mice. Mice were given an intramuscular injection of AAV8 275 
ProMyo or saline after 4 weeks of HFD-feeding. One group of mice was analysed 276 
after 2 weeks of myostatin inhibition (6-week total duration of HFD). At this time 277 
point, total body mass was not significantly greater in the HFD-fed mice (Figure 2A), 278 
but epididymal fat pad mass was significantly increased (Figure 2B), indicating 279 
visceral fat accumulation. We did not detect a significant difference in fasting or 280 
IPITT blood glucose levels between diet groups (Figure 2C), but HFD-fed mice 281 
displayed a delayed reduction in blood glucose levels in response to insulin (Figure 282 
2D), which is indicative of whole body insulin resistance. AAV8 ProMyo-injected TC 283 
muscles from both chow- and HFD-fed mice showed significant hypertrophy (+9.7% 284 
and +8.8% vs. saline, respectively; Figure 2E). However, neither chow-fed nor HFD-285 
fed mice showed an increase in glucose uptake into ProMyo-overexpressing TC 286 
muscles (Figure 2F). These data suggest that 2 weeks of myostatin inhibition in 287 
muscle is not sufficient to significantly increase insulin-stimulated glucose disposal in 288 
muscles of HFD-fed mice. 289 
 290 
After 10 weeks of myostatin inhibition (14 weeks of HFD-feeding), we observed a 291 
more severe metabolic phenotype. A significant increase in total body mass was 292 
detected (Figure 3A) and fat pad mass had increased to a greater extent in HFD-fed 293 
mice (Figure 3B). In addition, HFD-fed mice showed significantly higher fasting 294 
glucose levels than chow-fed controls and had a clearly delayed response to insulin 295 
during the IPITT (Figure 3C and 3D). Muscle mass was substantially greater in 296 
ProMyo overexpressing muscles than in saline-treated controls in both chow 297 
(+22.8%) and HFD (+23.2%) groups (Figure 3E). At this time point the ProMyo 298 
overexpressing muscles of the insulin-resistant HFD-fed mice showed significantly 299 
higher glucose uptake per unit mass during the IPITT than saline-injected controls 300 
(by ~78%) (Figure 3F). On this basis, total muscle glucose disposal can be estimated 301 
to be increased by 115–121% of that of control muscles. Taken together, these data 302 
suggest that 10 weeks of myostatin inhibition in mouse muscle specifically increases 303 
insulin-stimulated muscle glucose disposal in HFD-fed, but not chow-fed mice, 304 
despite the presence of significant muscle hypertrophy in both groups of mice. 305 
 306 
Effect of myostatin inhibition on potential regulators of insulin sensitivity 307 
We next determined whether myostatin inhibition selectively induced changes in 308 
pathways controlling GLUT translocation and/or expression in HFD-fed mice. 309 
Muscles from mice not subjected to IPITT were used for the analysis. Measurement 310 
of pro-myostatin mRNA, which includes the sequence for the inhibitory ProMyo 311 
peptide, showed robust overexpression of the ProMyo construct in muscles of chow- 312 
and HFD-fed mice after 10 weeks of myostatin inhibition (87±16-fold & 57±9-fold, 313 
respectively, Figure 4A). Slc2a1/GLUT1 mRNA levels were lower in ProMyo-314 
overexpressing muscles (Figure 4B). Slc2a4/GLUT4 mRNA levels were significantly 315 
lower in ProMyo-overexpressing muscles of HFD-fed mice compared to ProMyo-316 
overexpressing muscles of chow-fed mice (Figure 4C). GLUT1 and GLUT4 protein 317 
levels did not differ among any of the groups (Figure 4D-4F). These data suggest 318 
that, unexpectedly, GLUT expression was unaltered or reduced at the transcript level 319 
by myostatin inhibition. Basal Ser473 phosphorylation of Akt and Thr172 320 
phosphorylation of AMPKα were similar between diet groups or in ProMyo-321 
overexpressing muscles (Figure 5A & 5C). However, Akt protein levels were 322 
increased in ProMyo-overexpressing muscles of chow-fed mice, but not of HFD-fed 323 
mice (Figure 5B). AMPKα protein levels did not differ among the groups (Figure 5D). 324 
Likewise, basal Ser79 phosphorylation of acetyl-CoA carboxylase (ACC), which is 325 
indicative of AMPK activity, was similar among the groups (Figure 5E). ACC 326 
expression was increased in ProMyo-overexpressing muscles, although there was 327 
no significant difference within individual diet groups (Figure 5F). PGC-1α protein 328 
levels were significantly higher in HFD-fed mice but there was no effect of ProMyo 329 
overexpression (Figure 5G). These data suggest that the basal activities of pathways 330 
controlling GLUT expression and translocation were not specifically upregulated in 331 
HFD-fed mice by ProMyo overexpression.  332 
 333 
We explored the possibility that myostatin inhibition affects the expression of two 334 
more recently identified regulators of both myogenesis and muscle insulin sensitivity.  335 
Mitsugumin 53 (MG53) and Casitas B-cell lymphoma-b (Cbl-b) are E3 ligases that 336 
target the insulin receptor substrate 1 (IRS-1) for proteasomal degradation and their 337 
expression is thought to inhibit myoblast differentiation (42) and induce muscle 338 
atrophy during muscle unloading (29). Furthermore, MG53 is thought to induce 339 
muscle insulin resistance in response to high fat diet-feeding (31). Unexpectedly, 340 
transcript levels of MG53 were unaffected by HFD-feeding and were higher in 341 
ProMyo overexpressing muscles (Figure 6A). Cbl-b mRNA expression was not 342 
affected by ProMyo overexpression (Figure 6B), but its protein level was lower in 343 
HFD-fed mice (Figure 6C & 6D). Together, these data suggest unexpected changes 344 
in the expression of MG53 and Cbl-b in response to both high fat-diet feeding and 345 
myostatin inhibition that are unlikely to explain the observed effects on insulin-346 
stimulated muscle glucose disposal.   347 
 348 
Mitochondrial ribosomal protein transcripts are enriched after myostatin inhibition 349 
To obtain insight into possible alternative mechanisms for the effect of myostatin 350 
inhibition on skeletal muscle glucose uptake, we performed GSEA on transcriptomic 351 
data obtained from muscles from HFD-fed mice subjected to 10 weeks of myostatin 352 
inhibition and their paired saline-injected controls. We detected a 600-fold increase 353 
in IgG2A expression, which was due to the presence of IgG2A sequence in the AAV 354 
ProMyo-Fc construct. Therefore, this transcript was removed from the GSEA. To 355 
explain the observed increase in glucose uptake, we hypothesized that genes 356 
related to insulin signaling, fatty acid metabolism and oxidative phosphorylation may 357 
be enriched in the ProMyo overexpressing muscles. We detected significant 358 
enrichment of the KEGG_FATTY_ACID_METABOLISM gene set, but not of the 359 
KEGG_INSULIN_SIGNALING_PATHWAY or 360 
KEGG_OXIDATIVE_PHOSPHORYLATION gene sets (Table 2 & Table 3). It has 361 
been suggested that the effect of myostatin inhibition on glucose uptake in HFD-fed 362 
mice can be explained by reduced muscle inflammation (11). Therefore, we 363 
determined the enrichment of gene sets related to inflammation in our muscle 364 
samples. However, none of these gene sets showed significant enrichment in either 365 
saline-treated or ProMyo-overexpressing muscles (Table 2). 366 
To explore possible novel pathways involved in mediating the effect of myostatin 367 
inhibition on muscle glucose uptake, we repeated the GSEA with a large collection of 368 
gene sets based on gene ontologies. We found four gene sets that were enriched in 369 
ProMyo overexpressing muscles at a FDR of <5% (Table 2). These gene sets show 370 
a significant amount of overlap in that all contain mitochondrial ribosomal proteins. 371 
Subsequent analysis of the overlap in the genes responsible for the significant 372 
enrichment scores indeed mostly identified genes encoding mitochondrial ribosomal 373 
proteins and other genes involved in mitochondrial translation (Table 4), suggesting 374 
that myostatin inhibition increases the expression of these genes in the muscle of 375 
HFD-fed mice. Because the transcriptomic data suggest that the translation of 376 
mitochondrial DNA-encoded genes might be specifically enhanced, we analysed the 377 
protein levels of the nuclear DNA-encoded ubiquinol-cytochrome c reductase core 378 
protein 2 (UQCRC2) and succinate dehydrogenase complex iron sulfur subunit B 379 
(SDHB), and the mitochondrial DNA-encoded cytochrome c oxidase I (MTCO1). 380 
However, we found no differences in either the nuclear or mitochondrially encoded 381 
oxidative phosphorylation complex subunits among the groups (Figure 7).  382 
  383 
Discussion 384 
 385 
Myostatin inhibition is thought to improve muscle glucose disposal but the 386 
mechanisms whereby this is achieved and their quantitative importance are unclear. 387 
We show here that myostatin inhibition increases insulin-stimulated glucose disposal 388 
in skeletal muscle of HFD-fed mice, but not chow-fed mice, at a time point at which 389 
substantial muscle hypertrophy had occurred. Unexpectedly, this was not associated 390 
with higher expression of GLUT1/GLUT4 or PGC-1α, or basal phosphorylation of Akt 391 
or AMPK, which have been proposed to be regulators of the positive effects of 392 
myostatin inhibition on insulin sensitivity. However, we observed significant 393 
enrichment of genes involved in fatty acid metabolism and mitochondrial translation 394 
following myostatin inhibition. 395 
 396 
The lack of an effect of local myostatin inhibition on muscle insulin-stimulated 397 
glucose disposal in chow-fed mice was unexpected. Beneficial effects on glucose 398 
uptake and insulin sensitivity have been observed in multiple models of genetically 399 
induced muscle hypertrophy (6, 9, 10), implying the possibility of a common 400 
mechanism that leads to greater muscle glucose uptake. Furthermore, our previous 401 
experiments in rats demonstrated greater glucose disposal during an IPGTT after 17 402 
days of overexpression of the same ProMyo-Fc construct, which was associated with 403 
increased expression of GLUT1 and GLUT4 (8). However, muscle glucose uptake 404 
per unit muscle mass during an IPITT was unchanged throughout the full time 405 
course of the development of muscle hypertrophy (Figure 1C). This demonstrates 406 
that increases in muscle glucose disposal rate are not the inevitable result of 407 
myostatin inhibition-induced muscle hypertrophy. 408 
We observed significantly higher insulin-stimulated glucose disposal in ProMyo 409 
overexpressing muscles after 10 weeks, but not 2 weeks, of local myostatin inhibition 410 
in mice on an HFD (Figure 2F & 3F). The mice from the 10 week time point showed 411 
a more severe metabolic phenotype as a result of a longer duration of HFD feeding, 412 
with further increases in visceral fat accumulation, high fasting blood glucose and 413 
clear insulin resistance compared to the chow-fed mice and the two week time point 414 
(Figure 2 & 3). Despite this, glucose uptake was not lower in the muscles of the 415 
HFD-fed mice compared to those of the chow-fed mice (Figure 2F & 3F). Other 416 
groups have shown that feeding C57Bl/6 mice a similar HFD (i.e. 45% of calories 417 
from fat) for a similar or shorter amount of time leads to insulin resistance in TC 418 
muscle (37). The IPITT method we used to measure muscle glucose uptake involves 419 
a significant amount of variation between animals which can make it difficult to detect 420 
between-animal effects such as those of the diet.  421 
Nevertheless, our data suggest that the beneficial effect of myostatin inhibition on 422 
muscle glucose disposal requires a muscle hypertrophy-independent factor, which 423 
may be associated with the development of a severe metabolic phenotype. We have 424 
previously shown that local myostatin inhibition increases muscle glucose disposal to 425 
a much greater extent than muscle size in chow-fed rats (8), suggesting this factor 426 
may not be exclusively related to metabolic disease. Myostatin antibody treatment 427 
resulted in muscle hypertrophy in chow- and HFD-fed young mice and chow-fed old 428 
mice, but only increased whole body insulin sensitivity in the old mice (5). The 429 
absence of improvements in insulin sensitivity in young mice in the experiments by 430 
Camporez et al. might be explained by a requirement for a minimum level of 431 
hypertrophy in combination with the presence of a significant metabolic phenotype, 432 
as the mice from the 2 week myostatin inhibition time point in our study displayed a 433 
similar degree of hypertrophy, had been fed a HFD for a similar duration, and 434 
displayed no increase in glucose disposal with myostatin inhibition (Figure 2). 435 
However, it is unclear why an improvement was observed in old mice despite the 436 
presence of a similar degree of muscle hypertrophy in young mice.      437 
 438 
Together these data suggest that an increase in insulin-stimulated glucose disposal 439 
into muscle by postnatal myostatin inhibition in young mice requires a significant 440 
metabolic phenotype combined with a long duration of inhibition, although rats 441 
appear to be more sensitive to the effects of myostatin inhibition (8). The reason for 442 
the difference in the effect of ProMyo overexpression in chow-fed mice and rats is 443 
unclear. Our chow-fed mouse data set (Figure 1) includes a time point that is similar 444 
to the time point used in our previous rat study, at which the degree of hypertrophy 445 
was similar and at which we assessed glucose uptake during both an IPITT and an 446 
IPGTT, which was the test performed in the rats. It is possible that the larger content 447 
of the more insulin-sensitive type 1/2A muscle fibres in the rat TC muscle compared 448 
to that of the mouse TC muscle (~5/25% vs ~0/5%, respectively) played a role in the 449 
different response to myostatin inhibition, and that local myostatin inhibition in a 450 
mouse muscle with a fibre type composition more similar to that of the rat TC would 451 
have shown a similar increase in glucose uptake.  452 
 453 
The data have potential implications for the clinical translation of myostatin inhibition 454 
for the treatment of insulin resistance, as it may be that more obese individuals are 455 
more likely to benefit from myostatin inhibitors. Obesity does not appear to affect the 456 
degree of muscle hypertrophy resulting from myostatin inhibition (Figure 3E), and 457 
indeed the magnitude of the increase in insulin-stimulated glucose disposal exceeds 458 
that of the increase in muscle mass (Figure 3F). Thus, myostatin inhibition leads to 459 
substantial improvements in total insulin-stimulated muscle glucose disposal, which 460 
implies a treatment strategy utilising this approach would have positive effects in 461 
obese insulin resistant patients. 462 
 463 
Among the potential mechanisms which have been suggested to explain the positive 464 
effects of myostatin inhibition on muscle or whole body glucose uptake are higher 465 
expression of glucose transporters GLUT1 and GLUT4 (8), activation of Akt (27, 36), 466 
and stimulation of brown fat formation by increasing the secretion of the hormone 467 
irisin from skeletal muscle through an AMPK-PGC-1α-dependent mechanism (30). 468 
We did not demonstrate higher expression of any of these molecules in the ProMyo-469 
overexpressing TC muscles from HFD-fed mice (Figure 4 & 5), and we found no 470 
evidence of increased basal AMPK activity (Figure 5). However, we cannot exclude 471 
the possibility that GLUT translocation from the cytosol to the plasma membrane was 472 
increased separately of any effect on GLUT expression. There was an increase in 473 
PGC-1α protein levels in HFD mice, which is consistent with the existing literature 474 
(15), but there was no effect of ProMyo overexpression (Figure 5G). This brings into 475 
question whether myostatin inhibition in muscle is sufficient to increase PGC-1α 476 
expression. In support of this, lower PGC-1α protein levels have been detected in 477 
myostatin knockout mice (22) and lower PGC-1α transcript levels were found in mice 478 
treated with AAV ProMyo (28). In addition, we detected no increase  in expression of 479 
the insulin receptor-targeting E3 ligases MG53 and Cbl-b in HFD-fed mice, while 480 
myostatin inhibition unexpectedly increased the expression of MG53, which has 481 
previously been suggested to be responsible for muscle insulin resistance in 482 
response to HFD feeding (31) (Figure 6). Together, these data suggest that whole 483 
body insulin resistance was not associated with higher expression of these IRS-1-484 
targeting E3 ligases in muscle and that the improvement of muscle glucose disposal 485 
resulting from myostatin inhibition was not associated with a decrease in their 486 
expression. 487 
 488 
The results of our experiments are contrasting with existing hypotheses regarding 489 
the mechanism through which myostatin might increase skeletal muscle glucose 490 
disposal, and therefore suggest that other mechanisms exist. In accordance with 491 
previous observations (11) we found enrichment of gene sets associated with fatty 492 
acid (FA) oxidation including acyl-CoA synthases and acyl-CoA dehydrogenases 493 
(Table 2 & 3), which catalyse the initial steps in the beta-oxidation of FAs. We 494 
speculate that higher expression of these sets of genes could lead to improved 495 
metabolism of fatty acids, and thus greater insulin sensitivity. For example, an 496 
increase in carnitine palmitoyl transferase 1 (CPT1) activity (one of the genes which 497 
showed increased expression in ProMyo-overexpressing muscles) in skeletal muscle 498 
improves insulin sensitivity in HFD-fed mice (38). In addition, we observed 499 
enrichment of genes involved in mitochondrial translation, including those expressing 500 
mitochondrial ribosomal proteins, following myostatin inhibition in muscles of HFD-501 
fed mice (Table 2 & 4). Reductions in OXPHOS gene expression in human muscle 502 
have been associated with type 2 diabetes (26), but we found no significant 503 
enrichment of a gene set related to oxidative phosphorylation with myostatin 504 
inhibition (Table 2).  In accordance with this, we found no difference in the protein 505 
levels of two nuclear-encoded subunits of oxidative phosphorylation complexes 506 
(Figure 7A & 7B). The protein levels of a mitochondrially encoded protein also did 507 
not differ between saline-treated and ProMyo-overexpressing muscles (Figure 7C), 508 
which argues against a general increase in translation of mitochondrial proteins. 509 
Although any causal relationship between myostatin inhibition, changes in 510 
mitochondrial gene expression and improvements in muscle glucose uptake requires 511 
further investigation, it is possible that an enhancement in mitochondrial translation 512 
could explain why myostatin inhibition potentiates the effects of exercise on whole-513 
body insulin sensitivity and running distance in aged mice (18). 514 
 515 
We conclude that local post-natal myostatin inhibition improves insulin-stimulated 516 
muscle glucose disposal in obese HFD-fed mice. This is not secondary to muscle 517 
hypertrophy and is not observed in young insulin-sensitive mice. This effect does not 518 
appear to rely on the upregulation of glucose transporter and PGC-1α expression but 519 
was associated with expression changes in previously unidentified pathways related 520 
to mitochondrial function. These findings point towards further areas for future 521 
investigations into the mechanism of the effects of myostatin inhibition, and suggest 522 
that therapeutic myostatin inhibition may be effective in improving muscle glucose 523 
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 714 
  715 
Figure 1: AAV8 ProMyo increases muscle mass but not insulin-stimulated 716 
glucose disposal in chow-fed mice 717 
A: Mass of saline- or AAV8 ProMyo-injected tibialis cranialis (TC) muscle at 1, 2, 4 & 718 
10 weeks post-injection (n=10 per group). B: TC muscle masses of 2-month-old 719 
myostatin null mice 4 weeks after a single intramuscular injection of AAV8 ProMyo 720 
(n=3 per group). C: Glucose uptake per unit muscle mass during an intraperitoneal 721 
(i/p) insulin tolerance test (IPITT) at the indicated times after saline or AAV8 ProMyo 722 
injection. D: Total muscle glucose uptake at the indicated times after saline or AAV8 723 
ProMyo injection. E: Glucose uptake per unit muscle mass during an i/p glucose 724 
tolerance test (IPGTT) 2 weeks after saline or AAV8 ProMyo injection. Data are 725 
shown as mean + S.E.M. ** p<0.01 vs. Saline at the same time point. *** p<0.001 vs. 726 
Saline at the same time point. Two-way Repeated Measures ANOVA with Sidak-727 
Holm posthoc test (A, C, D); Paired t-test (B, E).   728 
 729 
Figure 2: Muscle insulin-stimulated glucose disposal is not affected by 2 730 
weeks of myostatin inhibition in mice on a high fat diet 731 
Body mass (A) and epididymal fat pad mass (B) of chow-fed and high fat diet (HFD)-732 
fed mice after 2 weeks of intramuscular ProMyo overexpression (n=10 per group). C: 733 
Blood glucose concentration during IPITT. D: Normalized blood glucose 734 
concentration during IPITT. Data in A-D are shown as mean +/- S.E.M. E: Muscle 735 
mass in chow-fed and HFD-fed mice 2 weeks after saline or AAV8 ProMyo injection. 736 
F: Glucose uptake into TC muscle during the IPITT. Bars in E & F show mean values 737 
and data points connected by a line represent contralateral muscle pairs from the 738 
same animal. ** Indicates p<0.01 vs. control. *** Indicates p<0.001 vs. control. 739 
Unpaired t-test (A, B); Two-way Repeated Measures ANOVA with Sidak-Holm 740 
posthoc test (C, D, E, F)   741 
Figure 3: Higher skeletal muscle insulin-stimulated glucose disposal after 10 742 
weeks of myostatin inhibition in mice on a high fat diet 743 
Body mass (A) and epididymal fat pad mass (B) of chow-fed and high fat diet (HFD)-744 
fed mice after 10 weeks of intramuscular ProMyo overexpression (n=10 per group). 745 
C: Blood glucose concentration during IPITT. D: Normalized blood glucose 746 
concentration during IPITT. Data in A-D are shown as mean +/- S.E.M. E: Muscle 747 
mass in chow-fed and HFD-fed mice 10 weeks after saline or AAV8 ProMyo 748 
injection. F: Glucose uptake into TC muscle during the IPITT. Bars in E & F show 749 
mean values and data points connected by a line represent contralateral muscle 750 
pairs from the same animal. * Indicates p<0.05 vs. control. ** Indicates p<0.01 vs. 751 
control. *** Indicates p<0.001 vs. control. Unpaired t-test (A, B); Two-way Repeated 752 
Measures ANOVA with Sidak-Holm posthoc test (C, D, E, F). 753 
 754 
 755 
Figure 4: Effect of 10 weeks of myostatin inhibition in HFD-fed mice on 756 
glucose transporter expression 757 
A-C: Real-time PCR analysis of ProMyo (A), Slc2a1/GLUT1 (B) and Slc2a4/GLUT4 758 
(C) transcript levels in chow- and HFD-fed mice (n=8 per group). A significant 759 
ANOVA main effect of ProMyo on GLUT1 transcript levels (B) is indicated. D & E: 760 
Western blot quantification of protein levels of GLUT1 (D, n=8 per group) and GLUT4 761 
(E, n=7-8 per group). F: Example western blot images. Samples from intra-animal 762 
muscle pairs are indicated by lines underneath the blot images. ProMyo (+) or saline 763 
(-) treatment is indicated. Data are shown as mean + S.E.M. * p<0.05. ** p<0.01. *** 764 
p<0.001. Two-way Repeated Measures ANOVA with Sidak-Holm posthoc test (A-E).  765 
  766 
Figure 5: Effect of 10 weeks of myostatin inhibition in HFD-fed mice on 767 
signalling pathways controlling glucose transporters 768 
A-G: Western blot quantification of phospho- and total levels of Akt (A & B), AMPK 769 
(C & D), ACC (E & F), and PGC-1α protein (G) (n=6-8 per group). Significant 770 
ANOVA main effects of ProMyo on ACC levels (F) and of diet on PGC-1α levels (G) 771 
are indicated. H: Example western blot images. Samples from intra-animal muscle 772 
pairs are indicated by lines underneath the blot images. ProMyo (+) or saline (-) 773 
treatment is indicated. The vertical spaces between blot images indicate lanes that 774 
were on the same blot but from which other lanes have been cropped out. Data are 775 
shown as mean + S.E.M. * p<0.05. ** p<0.01. Two-way Repeated Measures ANOVA 776 
with Sidak-Holm posthoc test (A-G).  777 
 778 
 779 
Figure 6: Effect of 10 weeks of myostatin inhibition in HFD-fed mice on insulin 780 
signalling-controlling E3 ligases 781 
A-B: Real-time PCR analysis of MG53 (A) and Cblb (B) transcript levels in chow and 782 
HFD-fed mice (n=8 per group). C: Western blot quantification of Cbl-b protein levels 783 
(n=8 per group). Significant ANOVA main effects of ProMyo on MG53 transcript 784 
levels (A) and of diet on Cbl-b protein levels (C) are indicated. D: Example western 785 
blot images. Samples from intra-animal muscle pairs are indicated by lines 786 
underneath the blot images. ProMyo (+) or saline (-) treatment is indicated. Data are 787 
shown as mean + S.E.M. * p<0.05. Two-way Repeated Measures ANOVA with 788 
Sidak-Holm posthoc test (A, B, C). 789 
 790 
  791 
Figure 7: Effect of 10 weeks of myostatin inhibition in HFD-fed mice on 792 
mitochondrial protein levels 793 
A-C: Western blot quantification of nuclear-encoded complex III subunit UQCRC2 794 
(A) and complex II subunit SDHB (B), and mitochondrially-encoded complex IV 795 
subunit MTCO1 (C) protein levels (n=8 per group). D: Example western blot images. 796 
Samples from intra-animal muscle pairs are indicated by lines underneath the blot 797 
images. ProMyo (+) or saline (-) treatment is indicated. Data are shown as mean + 798 
S.E.M. No significant differences were detected. Two-way Repeated Measures 799 



















Table 1: Sequences of primers used for real-time RT-PCR analysis 
 
Transcript  Primers Reference
ProMyo Fw: 5’-GGCACTGGTATTTGGCAGAG-3’ 
Rv: 5’-GTCCTGGGAAGGTTACAGCA-3’ 
 
Mstn exon 1 Fw: 5’-TGTTTATATTTACCTGTTCATGCTGAT-3’ 
Rv: 5’-GCCCCTCTTTTTCCACATTTTC-3’ 
 
Slc2a4/GLUT4 Fw: 5’-ACACTGGTCCTAGCTGTATTCT-3’ 
Rv: 5’-CCAGCCACGTTGCATTGTA-3’ 
 
Slc2a1/GLUT1 Fw: 5’-CGGGGTCTTAAGTGCGTCAG-3’ 
Rv: 5’-CTCCCACAGCCAACATGAGG-3’ 
 
MG53 Fw: 5’-TGTGTGCCTCGCTCGGTTC-3’ 
Rv: 5’-TCTGCTTCACGGTCCAGAGAA-3’ 
(31) 




Table 2: Gene set enrichment analysis of transcriptomics data from ProMyo 
overexpressing TA muscles of HFD-fed mice 
Size: Number of genes in gene set; ES: Enrichment score; NES: Normalized 
enrichment score; FDR: False discovery rate (Significance threshold: q<0.05). 
Positive ES indicates enrichment of gene set in ProMyo-overexpressing muscles, 
negative ES indicates enrichment in saline-treated muscles.  
 
Gene set Size ES NES FDR 
q value 
KEGG_FATTY_ACID_METABOLISM 34 0.57 1.93 0.003 
KEGG_OXIDATIVE_PHOSPHORYLATION 105 0.17 0.71 1.000 
KEGG_INSULIN_SIGNALING_PATHWAY 123 0.16 0.68 0.970 
     
GO_INFLAMMATORY_RESPONSE 454 -0.28 -1.39 0.145 
GO_MACROPHAGE_ACTIVATION 31 -0.44  -1.43 0.172 
GO_REGULATION_OF_MACROPHAGE_ACTIVATION 26 -0.35 -1.05 0.484 
GO_MACROPHAGE_DIFFERENTIATION 19 -0.54 -1.56 0.128 
GO_REGULATION_OF_MACROPHAGE_DIFFERENTIATION 20 -0.19 -0.57 0.986 
GO_LEUKOCYTE_ACTIVATION 414 -0.22 -1.13 0.357 
GO_T_CELL_MEDIATED_IMMUNITY 28 0.37 1.07 0.628 
GO_REGULATION_OF_T_CELL_PROLIFERATION 147 0.23 0.98 0.504 
GO_CYTOKINE_PRODUCTION 120 -0.22 -0.90 0.788 
GO_CYTOKINE_MEDIATED_SIGNALING_PATHWAY 452 -0.24 -1.18 0.359 
     
GO_TRANSLATIONAL_TERMINATION 86 0.53 2.14 0.024 
GO_ORGANELLAR_RIBOSOME 68 0.55 2.12 0.020 
GO_TRANSLATIONAL_ELONGATION 102 0.50 2.05 0.047 
GO_MITOCHONDRIAL_TRANSLATION 95 0.50 2.05 0.036 
Gene symbol Gene title Rank  
ACSL3 acyl-CoA synthetase long-chain family member 3 7
ACSL4 acyl-CoA synthetase long-chain family member 4 251
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 913
ECHS1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 1,412
ACSL6 acyl-CoA synthetase long-chain family member 6 1,568
CPT1A carnitine palmitoyltransferase 1A (liver) 1,781
ACADSB acyl-Coenzyme A dehydrogenase, short/branched chain 1,973
ACADS acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain 1,980
GCDH glutaryl-Coenzyme A dehydrogenase 2,575
ACSL1 acyl-CoA synthetase long-chain family member 1 2,974
ACAA2 acetyl-Coenzyme A acyltransferase 2 3,095
HADHA hydroxyacyl-Coenzyme A dehydrogenase, alpha subunit 3,181
ACADVL acyl-Coenzyme A dehydrogenase, very long chain 3,187
HADH hydroxyacyl-Coenzyme A dehydrogenase 3,398
ADH4 alcohol dehydrogenase 4 (class II), pi polypeptide 4,035
ACADL acyl-Coenzyme A dehydrogenase, long chain 4,169
 
Table 3: Leading edge genes of KEGG_FATTY_ACID_METABOLISM gene set 
enriched in ProMyo-overexpressing vs. saline-treated muscles 
Rank indicates the ranking of the gene in the list of all genes (total: 20,630) ranked 
on the basis of differential expression between ProMyo-overexpressing and saline-
treated muscles. 
 
Gene symbol Gene title Rank  
MTG1 mitochondrial GTPase 1 homolog (S. cerevisiae) 202
GFM2 G elongation factor, mitochondrial 2 257
MRPS22 mitochondrial ribosomal protein S22 381
MRPS33 mitochondrial ribosomal protein S33 476
MRPL22 mitochondrial ribosomal protein L22 609
MTERFD2 MTERF domain containing 2 738
MRPS35 mitochondrial ribosomal protein S35 752
MRPS12 mitochondrial ribosomal protein S12 874
MRPL21 mitochondrial ribosomal protein L21 964
MRPS5 mitochondrial ribosomal protein S5 1,159
MRPL19 mitochondrial ribosomal protein L19 1,230
ABTB1 ankyrin repeat and BTB (POZ) domain containing 1 1,280
MRPS31 mitochondrial ribosomal protein S31 1,539
MRPL44 mitochondrial ribosomal protein L44 1,556
EIF5A2 eukaryotic translation initiation factor 5A2 1,745
MRPL3 mitochondrial ribosomal protein L3 1,759
TUFM Tu translation elongation factor, mitochondrial 1,771
HARS histidyl-tRNA synthetase 1,963
MRP63 mitochondrial ribosomal protein 63 2,008
MRPL18 mitochondrial ribosomal protein L18 2,017
MTRF1L mitochondrial translational release factor 1-like 2,018
MRPS27 mitochondrial ribosomal protein S27 2,102
MRPL2 mitochondrial ribosomal protein L2 2,188
MRPL32 mitochondrial ribosomal protein L32 2,215
MRPL47 mitochondrial ribosomal protein L47 2,325
MRPS30 mitochondrial ribosomal protein S30 2,500
EEFSEC eukaryotic elongation factor, selenocysteine-tRNA-specific 2,759
MRPL55 mitochondrial ribosomal protein L55 2,762
MRPL24 mitochondrial ribosomal protein L24 2,865
MRPS18A mitochondrial ribosomal protein S18A 3,106
MRPL46 mitochondrial ribosomal protein L46 3,217
GFM1 G elongation factor, mitochondrial 1 3,349
MTIF2 mitochondrial translational initiation factor 2 3,428
EEF1D eukaryotic translation elongation factor 1 delta  3,519
MRPL40 mitochondrial ribosomal protein L40 3,558
MRPS18C mitochondrial ribosomal protein S18C 3,569
MRPS34 mitochondrial ribosomal protein S34 3,696
MRPS18B mitochondrial ribosomal protein S18B 3,709
MRPS28 mitochondrial ribosomal protein S28 3,786
MRPS25 mitochondrial ribosomal protein S25 3,787
GSPT1 G1 to S phase transition 1 3,828
MRPS2 mitochondrial ribosomal protein S2 3,956
MRPL14 mitochondrial ribosomal protein L14 3,988
MRPS6 mitochondrial ribosomal protein S6 4,178
MRPL51 mitochondrial ribosomal protein L51 4,218
MRPS16 mitochondrial ribosomal protein S16 4,225
MRRF mitochondrial ribosome recycling factor 4,419
MRPL54 mitochondrial ribosomal protein L54 4,603
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 4,640
NSUN4 NOL1/NOP2/Sun domain family, member 4 4,659
MRPL20 mitochondrial ribosomal protein L20 4,671
 
Table 4: Leading edge genes of gene ontology-based gene sets enriched in 
ProMyo-overexpressing vs. saline-treated muscles 
Rank indicates the ranking of the gene in the list of all genes (total: 20,630) ranked 
on the basis of differential expression between ProMyo-overexpressing and saline-
treated muscles. 
 
